# Aura Biosciences Inc. (AURA) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $7.56, market value $784 million.

## Valuation
- **P/E (trailing): n/a** (negative earnings). Aura Biosciences Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 2.5×**. The shares trade at 2.5× book value; book value is a meaningful part of the valuation.
- **Free-cash-flow yield: -13.2%** (5-yr avg -24.3%). Free cash flow is negative: the business is consuming cash, which is normal for heavy investment phases but a warning otherwise.

## Profitability
- **Return on equity: -77.6%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -0.6%**. Earnings per share fell 0.6%.

## Financial health
- **Current ratio: 8.15** (quick 8.15). Current assets cover the next year's liabilities 8.15 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. Aura Biosciences Inc. does not currently pay a dividend.

## Price and momentum
- **Total return (1 yr): 17.8%** (YTD 38.7%, 3-mo 14.0%). The shares are up 17.8% over twelve months including dividends.
- **From 52-week high: -20.7%** (59.8% above the low). Trading 21% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 51**. An RSI of 51 is neutral.
- **Beta (1 yr): 1.14** (volatility 57%). Beta of 1.14 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AURA · Page: https://foliofundamentals.com/stocks/aura

Not investment advice.